InsidersTradesSigma
Total declarations
Company
▲ Purchases (1 ops.)
▼ Sales (1 ops.)
Insider track record
ExecutiveDisclosed buys
1
Disclosed sells
1
T+90 hit rate
100%
T+90 mean return
+25.5%
Across 4 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Explore the complete record of transactions filed by Gayer Charles K, Directeur Commercial. Director active across 1 company, notably Biocryst Pharmaceuticals INC. In total, 16 disclosures have been recorded. Split: 1 buy · 1 sell. Total volume traded: €214k. History available since 14 December 2021. The latest transaction was disclosed on 22 December 2025 (Levée d'options). Regulator: SEC (Form 4). All data is free.
Companies and markets linked to Gayer Charles K
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations16 total
11,477 shares@ US$7.4110.4% of flowCommon StockSEC:0000882796-25-000041:0
14,142 shares@ US$3.225.6% of flowCommon StockSEC:0000882796-25-000041:1
10,091 shares@ US$5.046.2% of flowCommon StockSEC:0000882796-25-000041:2
50,000 shares@ US$5.5133.9% of flowCommon StockSEC:0000882796-25-000041:3
471,000 shares0Common StockSEC:0001171843-25-008038:0
8,181 shares@ US$7.577.1% of flowCommon StockSEC:0000882796-25-000036:0
125,950 shares0Common StockSEC:0001127602-24-029971:0
2,461 shares@ US$7.392.5% of flowCommon StockSEC:0001127602-24-029971:1
8,251 shares@ US$7.538.5% of flowCommon StockSEC:0001127602-24-029602:0
30,000 shares@ US$5.4721.9% of flowCommon StockSEC:0001127602-24-015363:0
Canonical exit: 11 Aug 2024 (T+90)
2,482 shares@ US$6.052.0% of flowCommon StockSEC:0001127602-23-030185:0
34,000 shares0Common StockSEC:0001127602-23-029833:0
34,000 shares0Common StockSEC:0001127602-22-028076:0
6,100 shares@ US$10.909.0% of flowCommon StockSEC:0001127602-22-027875:0
80,000 shares0Common StockSEC:0001127602-22-001454:0
125,000 shares0Common StockSEC:0001127602-21-031137:0
16 of 16 declarations
About Gayer Charles K
Charles K. Gayer is Chief Commercial Officer at Biocryst Pharmaceuticals Inc. He is responsible for the company's commercial strategy and business development. His expertise in the pharmaceutical sector is essential to support Biocryst's growth.
